LUMAKRASTM (Sotorasib) Now Approved

June 4, 2021

LUMAKRASTM (Sotorasib) Now Approved

LUMAKRASTM (Sotorasib) Now Approved for the Treatment of Adult Patients with KRAS G12C-mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Louisville, Ky. – Onco360®, the nation’s largest independent Oncology Pharmacy, has been selected by Amgen to be a specialty pharmacy partner for LUMAKRASTM (sotorasib), a new oral treatment for adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA-approved test, who have received at least one prior systemic therapy.

Onco360 is honored to be selected as a specialty pharmacy provider for LUMAKRAS in partnership with Amgen,” said Benito Fernandez, Chief Commercial Officer, Onco360. “The recent approval of LUMAKRAS unlocks the first FDA-approved treatment option for patients with previously treated advanced or metastatic KRAS G12C-mutant NSCLC. As a provider of this key treatment, Onco360 is committed to supporting the highly specialized needs of NSCLC patients.


According to the National Cancer Institute’s (NCI’s) Surveillance, Epidemiology, and End Results (SEER) program, 235,760 patients will be diagnosed with lung cancer in 2021, with a corresponding 131,880 deaths. When considering all stages and histologic subtypes of the disease, the five-year overall survival (OS) of lung cancer is 21.7%. Patients with Stage IV metastatic disease have a five-year OS of only 6.3%. Unfortunately, 56% of lung cancer patients have metastatic disease upon initial diagnosis. Up to 85% of lung cancer cases are classified as NSCLC.1 Approximately 13% of NSCLC patients have KRAS G12C mutations.2

LUMAKRAS is manufactured by Amgen, a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer. The FDA’s approval of LUMAKRAS comes as a result of a 124 patient subset of the Phase I/II CodeBreak 100 clinical trial (NCT03600883) which demonstrated that previously treated patients with metastatic KRAS G12C-mutant NSCLC experienced a 36% objective response rate (ORR) after LUMAKRAS administration.3 For full prescribing information, visit lumakras.com.



  1. National Cancer Institute Surveillance, Epidemiology, and End Results Program. Available at Lung and Bronchus Cancer — Cancer Stat Facts. Accessed May 2021.
  2. Understanding the KRAS G12C Mutation in Lung Cancer (lumakrashcp.com). Accessed June 2021.
  3. ashx (amgen.com). Accessed June 2021.


Media Contact:
Benito Fernandez, Chief Commercial Officer
[email protected]


Download Press Release